Current Headlines

  1. FDA Grants Orphan Drug Status To Bio Blast’s Cabaletta For Spinocerebellar Ataxia Type 3
    11/24/2014

    Bio Blast Pharma announced in a press release that the Food and Drug Administration (FDA) has granted Orphan Drug status to Cabaletta in the treatment of Spinocerebellar Ataxia type 3, the second Orphan designation for Cabaletta.

  2. FDA Fast Tracks Merrimack’s, Baxter’s MM-398 For Pancreatic Cancer
    11/24/2014

    Merrimack Pharmaceuticals announced in a press release that the Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal irinotecan injection) Fast Track designation.

  3. Basilea's BAL101553, Radiotherapy Delays Tumor Growth
    11/24/2014

    Compared to BAL101553 monotherapy, Basilea’s investigational agent combined with radiotherapy significantly delays tumor growth.

  4. Celldex’s Brain Cancer Vaccine Shows Promising Interim Results
    11/24/2014

    New Jersey-based biotech company Celldex Therapeutics has reported the positive interim results from a Phase 2 study of its novel brain cancer immunotherapy vaccine, rindopepimut, in patients with recurrent glioblastoma.

  5. BerGenBio’s AML Drug Granted FDA Orphan Status
    11/24/2014

    Oncology biopharmaceutical company BerGenBio announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug BGB324 as treatment for acute myeloid leukemia (AML).

  6. Documentum Life Sciences Strategy: Helping Customers Achieve Better Solution Value And Cloud Flexibility
    11/21/2014

    Life Sciences organizations are grappling with increasingly stringent regulatory requirements, globalization, pricing pressures and skyrocketing costs. The EMC Documentum for Life Sciences Solution Suite helps organizations address these challenges and meet compliance requirements, increase productivity, and securely collaborate across the extended enterprise.

  7. Vaccine & Gene Therapy Institute, TapImmune Partner On Cancer Vaccines
    11/21/2014

    The Vaccine & Gene Therapy Institute of Florida (VGTI), a non-profit research institute, and TapImmune have formed a partnership to develop TapImmune’s cancer vaccines.

  8. Tufts Report Puts Cost Of R&D At $2.6B Per New Drug
    11/21/2014

    It’s not a secret that developing a safe and effective drug is a long, arduous, and expensive process. A new study released this week estimates the approximate numbers. According to Tufts Center for the Study of Drug Development, the cost of developing a new drug from discovery to market is about $2.6 billion and is over a decade’s worth of work.

  9. Roche, Inovio End Pact On Prostate Cancer Drug
    11/21/2014

    Inovio Pharmaceuticals announced that it has ended its agreement with biotech giant Roche to jointly develop Inovio’s INO-5150 as immunotherapy for prostate cancer.

  10. Global Coalition Formed For Accelerating Drug Development For Brain Diseases
    11/21/2014

    A new coalition of nine charities and funding bodies has been formed to revive the development of promising drug candidates for neurodegenerative brain diseases — an initiative jumpstarted with roughly £30 million ($47 million) in funding.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.